Enhertu Beats Chemotherapy for HER2-Low and -Ultralow Metastatic Breast Cancer Jun 17, 2024 Enhertu seems better than chemotherapy for metastatic breast cancers with even the lowest detectable levels of HER2. Read more…
Enhertu Beats Chemotherapy for HER2-Low and -Ultralow Metastatic Breast Cancer Jun 17, 2024 Enhertu offers better survival than chemotherapy for pre-treated, metastatic, HER2-low or -ultralow breast cancer. Read more…
I'm making a list of questions for my oncologist appointment coming up and in looking at posts relative to metformin I came across neratinib. I realize the metformin trial ended up demonstrating that it was not beneficial in lessening recurrence rates. But apparently neratinib trials were because it was approved by the FDA…